New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations ...

The general approach should be a combination of rituximab and chemotherapy ... Therapeutic options for relapsed follicular lymphoma include the same traditional regimens used for first-line ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

In the era of rituximab, whether ASCT is needed in the treatment of follicular lymphoma remains a valid question. In the retrospective GELA study, both rituximab and ASCT had a benefit on patients ...

SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to ...

What’s the next step for this patient with a 4-year history of low-grade follicular lymphoma and who now ... with 6 cycles of bendamustine and rituximab (BR), and has been monitored clinically ...

Branded as Rituxan Hycela, subcutaneous rituximab is administered in combination with hyaluronidase human and is approved for adults with follicular lymphoma, diffuse large B-cell lymphoma and ...

lenalidomide and rituximab in patients with advanced follicular lymphoma. Caimi explained that the findings showed that “1 year of the triplet combination seems to be better than the doublet in ...

For the follicular lymphoma trial, patients receiving loncastuximab and rituximab had a 67% complete response rate, meaning their cancer could no longer be detected by imaging, and an overall ...

All patients with follicular ... therapy of lymphoma." The study included 86 patients with B-cell lymphomas, 18 of whom received FT596 after conditioning chemotherapy without rituximab, and ...